KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Current Liabilities (2018 - 2025)

Vir Biotechnology's Total Current Liabilities history spans 8 years, with the latest figure at $92.8 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 22.44% year-over-year to $92.8 million; the TTM value through Dec 2025 reached $92.8 million, down 22.44%, while the annual FY2025 figure was $92.8 million, 22.44% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $92.8 million at Vir Biotechnology, up from $75.2 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $702.4 million in Q1 2022 and bottomed at $75.2 million in Q3 2025.
  • The 5-year median for Total Current Liabilities is $229.7 million (2021), against an average of $279.3 million.
  • The largest annual shift saw Total Current Liabilities surged 540.29% in 2021 before it crashed 65.68% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $341.2 million in 2021, then soared by 49.76% to $511.0 million in 2022, then plummeted by 65.68% to $175.4 million in 2023, then plummeted by 31.78% to $119.7 million in 2024, then fell by 22.44% to $92.8 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Total Current Liabilities are $92.8 million (Q4 2025), $75.2 million (Q3 2025), and $119.7 million (Q4 2024).